Common Photosensitizing Drugs Increase Skin Cancer Risk
By Lori Solomon HealthDay Reporter
TUESDAY, April 1, 2025 -- Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology, Photoimmunology & Photomedicine.
Gustav Boelsgaard Christensen, from Skåne University Hospital in Lund, Sweden, and colleagues assessed whether the use of commonly prescribed photosensitizing drugs increases skin cancer risk.
The researchers found that hormone replacement therapy significantly increased the risk for basal cell carcinoma (BCC; hazard ratio [HR], 1.24), cutaneous squamous cell carcinoma (cSCC; HR 1.23), and cutaneous malignant melanoma (cM; HR, 1.31), with estrogen driving the risk. There was a trend observed between a higher risk for BCC and cM and higher doses of estrogen treatment. Among individuals using diuretics, loop diuretics were associated with increased cSCC risk (HR, 1.6), including a positive association between risk and dose. Thiazide use was tied to increased risks for BCC (HR, 1.25) and cM (HR, 1.41). There was a possible curvilinear association between nonsteroidal anti-inflammatory drugs and BCC and cSCC.
"We suggest that physicians should advise female patients prescribed estrogen, thiazides, or loop diuretics to limit their sun exposure," the authors write. "Future well-designed prospective studies are warranted to further investigate the relationships between common photosensitizing drugs and the risk of skin cancer."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Survey Reveals Women May Be Experiencing Perimenopause in Their 40s
FRIDAY, April 25, 2025 -- Six in 10 women believe they will hit menopause in their 40s, according to survey results released April 8 by The Ohio State University Wexner Medical...
Melphalan/Hepatic Delivery System Beneficial for Metastatic Uveal Melanoma
THURSDAY, April 24, 2025 -- For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and...
Circulating Tumor DNA Can ID Outcomes for Patients With Melanoma
WEDNESDAY, April 16, 2025 -- Droplet digital polymerase chain reaction (PCR) measurements of cell-free, circulating tumor DNA (ctDNA) can identify patients with melanoma and a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.